【新聞公告】火星生技與直播天后丟丟妹簽約 開創火星直播商機與規劃全新品牌！MARX Biotech Joins Forces with Livestream Superstar “Diudiu33”！
聚焦大健康零售市場的新零售公司火星生技*（股票代碼：7731）持續積極拓展直播業務，今年開創火星直播平台，深耕國內及星馬直播營銷市場，更迎來直播天后李明珊（藝名「丟丟妹」）加入，雙方於昨（30）日舉行簽約儀式，拓展火星生技商品的直播市場，並規劃共創火星生技第五個全新品牌。火星生技與李明珊（丟丟妹）將在線上線下通路協作、多元品牌經營、分眾市場以及各自優勢與資源融合的基礎上，共同強化國內外大健康零售市場的競爭力。李明珊（丟丟妹）曾創下單月營業額2億元的銷售紀錄，憑藉其在網路直播市場與既有客群所建立的知名度，可望將火星生技旗下各品牌切入國內外直播市場，帶動營收再加速跳升，為股東創造價值。
火星生技利用OMO（Online merge Offline）建構大健康新零售通路平台，透過活躍且自建的B2B系統，掌握3,400家實體藥妝藥局通路，深度合作幫助藥局營利，聯手擴大市場規模。今年火星生技加強直播平台，開創直播銷售網頁，於品牌官網、國內與海外線上購物平台之外，更主動觸及社群消費，擴大品牌影響力。註：直播銷售網頁 ： https://marxlive.shoplineapp.com/
未來李明珊（丟丟妹）每月將在火星生技平台及個人直播平台播出火星及自創品牌商品，此自創品牌將成為火星生技第五個品牌，拓展目標藍海市場。以李明珊（丟丟妹）擁兩大直播平台逾155萬粉絲數的實力，預期將為火星生技旗下各品牌產品創造一波又一波的銷售佳績。火星生技在今年淡季之中，前四月營收即成長了3倍，接續而來的618購物節、父親節、雙11、雙12、周年慶等購物旺季表現更值得期待，加上李明珊（丟丟妹）帶動的直播商機，更加如虎添翼，全年營收成長幅度可望再超越前四月。
火星生技目前經營四個不同市場定位的品牌，包括：Taizaku、藥師健生活、inyouso及樹飛雪，針對不同族群的生活需求進而開發系列產品，搭配火星生技深耕線上與線下通路，在激烈的保健品市場中脫穎而出，營收正在高速成長階段，2023年營收成長162.04％至2.90億元，今年前四月營收1.42億元再較2023年同期成長314.01％，並已達到去年全年營收的五成。各品牌除了原有產品成長曲線仍在加速，每個品牌每年持續推出1-2個新產品，以深耕既有受眾，保持品牌成長空間。
火星生技持續合併國內外品牌及拓展國內外藥局和跨境銷售通路，中期目標是佔據藥局保健品收入20％。以平均一家藥局販賣超過2,000個保健品項而言，目前火星生技旗下品牌超過120品項，仍有相當充足的空間繼續擴大市占。火星生技將複製合併藥師健生活、樹飛雪的成功商業模式，積極整合台灣與其他區域中小型保健品牌商，包含自行創立或合併，每年新增3-10個品牌，拓展目標受眾，以完整的產品線，透過獨家B2B系統(PharBuy)，滿足藥局採購需求，達到藥局裡都有火星生技產品的目標，成為大健康領域的領頭羊。
Marx Biotech (7731 TT), a leading player in the health retail sector, has announced a strategic alliance with renowned livestreaming influencer Sammi Li, also known by her stage name "Diudiu 33" , as part of its ongoing efforts to expand its livestreaming business. This collaboration aims to leverage livestreaming to expand Marx Biotech’s market presence and to develop the fifth new brand under the Marx umbrella.
The signing ceremony took place yesterday (30th ), marking a significant step in Marx Biotech’s ambition to dominate both domestic and Southeast Asian markets. Diudiu33 will help promote Mars Biotech’s products through her extensive online presence, bringing her expertise and following to the company. This partnership will focus on integrating online and offline channels, brand diversification, segmented market strategies, and combining their strengths to enhance competitiveness in the global health retail market.
"Strengthening Market Position through OMO Integration"
Marx Biotech's innovative Online Merge Offline (OMO) strategy underpins its retail platform, encompassing a robust B2B system that manages over 3,400 physical pharmacy and drugstore channels. This system not only aids pharmacies in boosting their profitability but also scales market reach. This year, Marx Biotech has intensified its focus on livestreaming with the launch of its sales website, aiming to broaden its influence beyond official websites and domestic and international e-commerce platforms by engaging directly with social media audiences. ※Sales website：https://marxlive.shoplineapp.com/
"Livestream Diva Set to Drive Another Wave of Growth"
Diudiu 33, who has a remarkable sales record of NT$200 million in a single month, brings her extensive network of over 1.55 million followers across two major livestreaming platforms to the partnership. She is set to promote Marx Biotech’s products and her own newly developed brand, which will become Marx Biotech’s fifth brand, through regular livestreams. This new venture targets untapped markets, leveraging Diudiu’s popularity to drive significant sales growth.
Marx Biotech has already reported a threefold increase in revenue in the first four months of the year, even during a typically slow season. With upcoming peak shopping events such as the 618 Shopping Festival, Father's Day, Double 11, Double 12, and anniversary sales, the addition of Diudiu’s livestreaming influence is expected to further accelerate revenue growth, surpassing the gains achieved in the early part of the year.
"Diverse Brand and Market Expansion Spurs Rapid Revenue Increase"
Currently, Marx Biotech manages four distinct brands—Taizaku, Phargoods, Inyouso, and SnowIOU—each designed to meet the varied needs of different consumer segments. By leveraging its comprehensive online and offline distribution channels, Marx Biotech continues to stand out in the competitive health products market. In 2023, the company achieved a 162.04% increase in revenue, reaching NT$290 million. For the first four months of this year, revenue surged by 314.01% compared to the same period in 2023, already accounting for 50% of last year’s total revenue. Each brand is expected to release 1-2 new products annually, ensuring continued growth and engagement with existing audiences.
"A Clear Roadmap for Expansive Growth"
Marx Biotech remains committed to expanding both its domestic and international brand portfolio and distribution channels. The mid-term goal is to capture 20% of pharmacy health product sales. With over 2,000 health product items available in an average pharmacy, Marx Biotech’s current offering of more than 120 products indicates significant potential for market share growth. The company plans to replicate the successful business models of Phargoods and SnowIOU by integrating and acquiring small to mid-sized health brands across Taiwan and other regions, targeting the addition of 3-10 new brands annually. This strategy aims to create a comprehensive product line, supported by its exclusive B2B system (PharBuy), fulfilling pharmacy procurement needs and solidifying Marx Biotech’s position as a leader in the health sector.
火星生技利用OMO（Online merge Offline）建構大健康新零售通路平台，透過活躍且自建的B2B系統，掌握3,400家實體藥妝藥局通路，深度合作幫助藥局營利，聯手擴大市場規模。今年火星生技加強直播平台，開創直播銷售網頁，於品牌官網、國內與海外線上購物平台之外，更主動觸及社群消費，擴大品牌影響力。註：直播銷售網頁 ： https://marxlive.shoplineapp.com/
未來李明珊（丟丟妹）每月將在火星生技平台及個人直播平台播出火星及自創品牌商品，此自創品牌將成為火星生技第五個品牌，拓展目標藍海市場。以李明珊（丟丟妹）擁兩大直播平台逾155萬粉絲數的實力，預期將為火星生技旗下各品牌產品創造一波又一波的銷售佳績。火星生技在今年淡季之中，前四月營收即成長了3倍，接續而來的618購物節、父親節、雙11、雙12、周年慶等購物旺季表現更值得期待，加上李明珊（丟丟妹）帶動的直播商機，更加如虎添翼，全年營收成長幅度可望再超越前四月。
火星生技目前經營四個不同市場定位的品牌，包括：Taizaku、藥師健生活、inyouso及樹飛雪，針對不同族群的生活需求進而開發系列產品，搭配火星生技深耕線上與線下通路，在激烈的保健品市場中脫穎而出，營收正在高速成長階段，2023年營收成長162.04％至2.90億元，今年前四月營收1.42億元再較2023年同期成長314.01％，並已達到去年全年營收的五成。各品牌除了原有產品成長曲線仍在加速，每個品牌每年持續推出1-2個新產品，以深耕既有受眾，保持品牌成長空間。
火星生技持續合併國內外品牌及拓展國內外藥局和跨境銷售通路，中期目標是佔據藥局保健品收入20％。以平均一家藥局販賣超過2,000個保健品項而言，目前火星生技旗下品牌超過120品項，仍有相當充足的空間繼續擴大市占。火星生技將複製合併藥師健生活、樹飛雪的成功商業模式，積極整合台灣與其他區域中小型保健品牌商，包含自行創立或合併，每年新增3-10個品牌，拓展目標受眾，以完整的產品線，透過獨家B2B系統(PharBuy)，滿足藥局採購需求，達到藥局裡都有火星生技產品的目標，成為大健康領域的領頭羊。
Marx Biotech (7731 TT), a leading player in the health retail sector, has announced a strategic alliance with renowned livestreaming influencer Sammi Li, also known by her stage name "Diudiu 33" , as part of its ongoing efforts to expand its livestreaming business. This collaboration aims to leverage livestreaming to expand Marx Biotech’s market presence and to develop the fifth new brand under the Marx umbrella.
The signing ceremony took place yesterday (30th ), marking a significant step in Marx Biotech’s ambition to dominate both domestic and Southeast Asian markets. Diudiu33 will help promote Mars Biotech’s products through her extensive online presence, bringing her expertise and following to the company. This partnership will focus on integrating online and offline channels, brand diversification, segmented market strategies, and combining their strengths to enhance competitiveness in the global health retail market.
"Strengthening Market Position through OMO Integration"
Marx Biotech's innovative Online Merge Offline (OMO) strategy underpins its retail platform, encompassing a robust B2B system that manages over 3,400 physical pharmacy and drugstore channels. This system not only aids pharmacies in boosting their profitability but also scales market reach. This year, Marx Biotech has intensified its focus on livestreaming with the launch of its sales website, aiming to broaden its influence beyond official websites and domestic and international e-commerce platforms by engaging directly with social media audiences. ※Sales website：https://marxlive.shoplineapp.com/
"Livestream Diva Set to Drive Another Wave of Growth"
Diudiu 33, who has a remarkable sales record of NT$200 million in a single month, brings her extensive network of over 1.55 million followers across two major livestreaming platforms to the partnership. She is set to promote Marx Biotech’s products and her own newly developed brand, which will become Marx Biotech’s fifth brand, through regular livestreams. This new venture targets untapped markets, leveraging Diudiu’s popularity to drive significant sales growth.
Marx Biotech has already reported a threefold increase in revenue in the first four months of the year, even during a typically slow season. With upcoming peak shopping events such as the 618 Shopping Festival, Father's Day, Double 11, Double 12, and anniversary sales, the addition of Diudiu’s livestreaming influence is expected to further accelerate revenue growth, surpassing the gains achieved in the early part of the year.
"Diverse Brand and Market Expansion Spurs Rapid Revenue Increase"
Currently, Marx Biotech manages four distinct brands—Taizaku, Phargoods, Inyouso, and SnowIOU—each designed to meet the varied needs of different consumer segments. By leveraging its comprehensive online and offline distribution channels, Marx Biotech continues to stand out in the competitive health products market. In 2023, the company achieved a 162.04% increase in revenue, reaching NT$290 million. For the first four months of this year, revenue surged by 314.01% compared to the same period in 2023, already accounting for 50% of last year’s total revenue. Each brand is expected to release 1-2 new products annually, ensuring continued growth and engagement with existing audiences.
"A Clear Roadmap for Expansive Growth"
Marx Biotech remains committed to expanding both its domestic and international brand portfolio and distribution channels. The mid-term goal is to capture 20% of pharmacy health product sales. With over 2,000 health product items available in an average pharmacy, Marx Biotech’s current offering of more than 120 products indicates significant potential for market share growth. The company plans to replicate the successful business models of Phargoods and SnowIOU by integrating and acquiring small to mid-sized health brands across Taiwan and other regions, targeting the addition of 3-10 new brands annually. This strategy aims to create a comprehensive product line, supported by its exclusive B2B system (PharBuy), fulfilling pharmacy procurement needs and solidifying Marx Biotech’s position as a leader in the health sector.